PH12016502431A1 - Composition and methods for administration of vaccines against dengue virus - Google Patents

Composition and methods for administration of vaccines against dengue virus

Info

Publication number
PH12016502431A1
PH12016502431A1 PH12016502431A PH12016502431A PH12016502431A1 PH 12016502431 A1 PH12016502431 A1 PH 12016502431A1 PH 12016502431 A PH12016502431 A PH 12016502431A PH 12016502431 A PH12016502431 A PH 12016502431A PH 12016502431 A1 PH12016502431 A1 PH 12016502431A1
Authority
PH
Philippines
Prior art keywords
against dengue
dengue virus
den
composition
methods
Prior art date
Application number
PH12016502431A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jorge E Osorio
Charalambos D Partidos
Joseph N Brewoo
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43220488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12016502431(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of PH12016502431A1 publication Critical patent/PH12016502431A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12016502431A 2009-06-01 2016-12-05 Composition and methods for administration of vaccines against dengue virus PH12016502431A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18302009P 2009-06-01 2009-06-01
PCT/US2010/036726 WO2010141386A1 (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Publications (1)

Publication Number Publication Date
PH12016502431A1 true PH12016502431A1 (en) 2019-02-11

Family

ID=43220488

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016502431A PH12016502431A1 (en) 2009-06-01 2016-12-05 Composition and methods for administration of vaccines against dengue virus

Country Status (17)

Country Link
US (2) US9211323B2 (https=)
EP (1) EP2438198A4 (https=)
JP (2) JP5848243B2 (https=)
KR (1) KR101876304B1 (https=)
CN (2) CN102449172A (https=)
AU (3) AU2010256845B2 (https=)
CA (1) CA2763944A1 (https=)
CL (1) CL2011003043A1 (https=)
CO (1) CO6470882A2 (https=)
CU (1) CU20110219A7 (https=)
IL (2) IL216706A0 (https=)
MX (1) MX343172B (https=)
MY (1) MY184428A (https=)
NZ (2) NZ597000A (https=)
PH (1) PH12016502431A1 (https=)
SG (1) SG176299A1 (https=)
WO (1) WO2010141386A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
NZ630831A (en) * 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
US11007261B2 (en) 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU718740B2 (en) * 1995-11-14 2000-04-20 Institut Pasteur Polyvalent anti-dengue vaccine
US20070087015A1 (en) * 1999-03-26 2007-04-19 Eckels Kenneth I Multivalent dengue virus vaccine
WO2008065315A1 (fr) * 2006-12-01 2008-06-05 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231570T2 (de) * 1991-09-19 2001-06-21 Us Of America Represented By D Chimäre und/oder wachstumgehemmte Flaviviren
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DK2290109T3 (da) 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
JP4993301B2 (ja) * 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US7618393B2 (en) * 2005-05-03 2009-11-17 Pharmajet, Inc. Needle-less injector and method of fluid delivery
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CN101287490B (zh) * 2005-08-10 2013-04-24 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种
US20080193477A1 (en) 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
DK2589602T3 (en) * 2006-08-15 2016-07-25 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of dengue virus vaccine components
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU718740B2 (en) * 1995-11-14 2000-04-20 Institut Pasteur Polyvalent anti-dengue vaccine
US20070087015A1 (en) * 1999-03-26 2007-04-19 Eckels Kenneth I Multivalent dengue virus vaccine
WO2008065315A1 (fr) * 2006-12-01 2008-06-05 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
AU2016277660A1 (en) 2017-01-12
CL2011003043A1 (es) 2012-07-20
US10010600B2 (en) 2018-07-03
CN102449172A (zh) 2012-05-09
MY184428A (en) 2021-04-01
CA2763944A1 (en) 2010-12-09
KR101876304B1 (ko) 2018-07-10
JP5848243B2 (ja) 2016-01-27
JP2012528794A (ja) 2012-11-15
JP2016033151A (ja) 2016-03-10
WO2010141386A1 (en) 2010-12-09
IL216706A0 (en) 2012-02-29
CN107913406A (zh) 2018-04-17
KR20120027396A (ko) 2012-03-21
AU2010256845B2 (en) 2016-09-22
US20100303860A1 (en) 2010-12-02
US20160129102A1 (en) 2016-05-12
NZ618158A (en) 2015-05-29
CU20110219A7 (es) 2012-06-21
US9211323B2 (en) 2015-12-15
AU2010256845A1 (en) 2011-12-22
NZ597000A (en) 2014-07-25
MX343172B (es) 2016-10-26
EP2438198A4 (en) 2014-05-14
MX2011012807A (es) 2012-01-30
AU2019200212A1 (en) 2019-01-31
CO6470882A2 (es) 2012-06-29
EP2438198A1 (en) 2012-04-11
IL243204A0 (en) 2016-02-29
SG176299A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
PH12016502431A1 (en) Composition and methods for administration of vaccines against dengue virus
MX374519B (es) Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
MY180698A (en) Immunization protocol against the 4 dengue serotypes
MX336687B (es) Tratamiento y prevencion de infecciones del virus del dengue.
GEP20237575B (en) Stable vaccine compositions comprising inter alia live attenuated recombinant dengue virus and process for preparation thereof
IL210289A0 (en) Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
PE20140646A1 (es) Vacuna de virus de dengue inactivado
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
MY169275A (en) Method of immunization against the four serotypes of dengue
MY192806A (en) Compositions and methods of vaccination against dengue virus in children and young adults
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
ECSP12012131A (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2007015783A3 (en) Attenuated strains of flaviviruses , and uses thereof
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
WO2012178196A3 (en) Protection against dengue virus and prevention of severe dengue disease
AR082057A1 (es) Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (i)
HK1169149A (en) Compositions and methods for administration of vaccines against dengue virus
TH91621B (th) วิธีการของการก่อภูมิคุ้มกันโรคเพื่อต่อต้าน 4 ซีโรไทป์ของไข้เลือดออก
TH137870A (th) องค์ประกอบและวิธีการสำหรับการให้ของวัคซีนต่อต้านไวรัสเดงกี่ (dengue virus)